Monitoring and management of hyperglycemia in patients with advanced diabetic kidney disease

Escott, Gustavo Monteiro; Silveira, Letícia Guimarães da; Cancelier, Vítor da Agostim; Dall’Agnol, Angélica; Silveiro, Sandra Pinho

doi:10.1016/j.jdiacomp.2020.107774

Cited by 7 publications

(4 citation statements)

References 143 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Estimated GFR must be considered regarding the use of medications for glycemic control in DKD. Table 2 shows the dose adjustments of the antidiabetic medications according to the stage of DKD [ 75 ] (Table 3 ).…”

Section: Prevention Of Dkd Progressionmentioning

confidence: 99%

See 2 more Smart Citations

The 2021–2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD

Sá

Rangel

Canani

et al. 2022

Diabetol Metab Syndr

View full text Add to dashboard Cite

Background Diabetic kidney disease is the leading cause of end-stage renal disease and is associated with increased morbidity and mortality. This review is an authorized literal translation of part of the Brazilian Diabetes Society (SBD) Guidelines 2021–2022. This evidence-based guideline provides guidance on the correct management of Diabetic Kidney Disease (DKD) in clinical practice. Methods The methodology was published elsewhere in previous SBD guidelines and was approved by the internal institutional Steering Committee for publication. Briefly, the Brazilian Diabetes Society indicated 14 experts to constitute the Central Committee, designed to regulate methodology, review the manuscripts, and make judgments on degrees of recommendations and levels of evidence. SBD Renal Disease Department drafted the manuscript selecting key clinical questions to make a narrative review using MEDLINE via PubMed, with the best evidence available including high-quality clinical trials, metanalysis, and large observational studies related to DKD diagnosis and treatment, by using the MeSH terms [diabetes], [type 2 diabetes], [type 1 diabetes] and [chronic kidney disease]. Results The extensive review of the literature made by the 14 members of the Central Committee defined 24 recommendations. Three levels of evidence were considered: A. Data from more than 1 randomized clinical trial or 1 metanalysis of randomized clinical trials with low heterogeneity (I2 < 40%). B. Data from metanalysis, including large observational studies, a single randomized clinical trial, or a pre-specified subgroup analysis. C: Data from small or non-randomized studies, exploratory analyses, or consensus of expert opinion. The degree of recommendation was obtained based on a poll sent to the panelists, using the following criteria: Grade I: when more than 90% of agreement; Grade IIa 75–89% of agreement; IIb 50–74% of agreement, and III, when most of the panelist recommends against a defined treatment. Conclusions To prevent or at least postpone the advanced stages of DKD with the associated cardiovascular complications, intensive glycemic and blood pressure control are required, as well as the use of renin–angiotensin–aldosterone system blocker agents such as ARB, ACEI, and MRA. Recently, SGLT2 inhibitors and GLP1 receptor agonists have been added to the therapeutic arsenal, with well-proven benefits regarding kidney protection and patients’ survival.

show abstract

Section: Prevention Of Dkd Progressionmentioning

confidence: 99%

“…Exp. : limited experience; GFR: Glomerular filtration rate; Source: Adapted from Escott et al [ 75 ]…”

Section: Prevention Of Dkd Progressionmentioning

confidence: 99%

See 1 more Smart Citation

The 2021–2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD

Sá

Rangel

Canani

et al. 2022

Diabetol Metab Syndr

View full text Add to dashboard Cite

show abstract

“…Specifically, hyperglycemia is defined as a condition in which the blood sugar level is consistently between 5.6 and 7.0 mmol L -1 (100-126 mg dl -1 ), whereas diabetes is defined as a condition in which the blood sugar level is greater than 7.0 mmol L -1 (126 mg dl -1 ) (American Diabetes Association Professional Practice Committee 2021). Endocrine abnormalities, end-stage terminal disease, significant operations, and a prolonged unhealthy lifestyle such as excessive high-calorie eating, being overweight, and high amounts of stress are all common risk factors for acquiring this syndrome (Abideen et al, 2017;Escott et al, 2021;Riddle et al, 2021;Zhang et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Ameliorative Effect of Jamaican Cherry (Muntingia calabura L.) Leaf Extract Toward Glucose Control and Immune Cells Modulation in High Fat Diet-Administrated Mice

Putra,

Shofiyah,

Rahim

et al. 2024

Yüzüncü Yıl Üniversitesi Tarım Bilimleri Dergisi

View full text Add to dashboard Cite

Hyperglycemia is a dangerous condition in which too much glucose circulates in the blood plasma and is the leading cause of diabetes mellitus. It is a complex condition with varying degrees that can change over time, mainly owing to metabolic factors that reduce insulin secretion, decrease glucose use, and increase glucose production. This study aims to evaluate Muntingia calabura leaf extract's effect on glucose control and immune cell modulation in high-fat diet-administrated mice. According to the result, we found that M. calabura leaf extract significantly reduced the fasting blood sugar. Importantly, M. calabura leaf extract exerts immunomodulation effects by suppressing the relative number of regulatory T cells in the hypoglycemic mice model. Finally, this study showed M. calabura leaf extract exerts ameliorative potency against hyperglycemia by lowering the blood sugar level and suppressing the regulatory T cells. These results suggested that M. calabura leaf extract could develop into complementary and alternative medicine.

show abstract

Diabetic Nephropathy

Kelly

Solomon

2023

Contemporary Cardiology

View full text Add to dashboard Cite

Monitoring and management of hyperglycemia in patients with advanced diabetic kidney disease

Cited by 7 publications

References 143 publications

The 2021–2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD

The 2021–2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD

Ameliorative Effect of Jamaican Cherry (Muntingia calabura L.) Leaf Extract Toward Glucose Control and Immune Cells Modulation in High Fat Diet-Administrated Mice

Diabetic Nephropathy

Contact Info

Product

Resources

About